AU2001259706A1 - Polymeric compounds useful as prodrugs - Google Patents

Polymeric compounds useful as prodrugs

Info

Publication number
AU2001259706A1
AU2001259706A1 AU2001259706A AU5970601A AU2001259706A1 AU 2001259706 A1 AU2001259706 A1 AU 2001259706A1 AU 2001259706 A AU2001259706 A AU 2001259706A AU 5970601 A AU5970601 A AU 5970601A AU 2001259706 A1 AU2001259706 A1 AU 2001259706A1
Authority
AU
Australia
Prior art keywords
prodrugs
compounds useful
polymeric compounds
polymeric
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259706A
Inventor
Sourena Nadji
Umashanker Sampath
Joseph A. Toce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reliable Biopharmaceutical LLC
Original Assignee
Reliable Biopharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliable Biopharmaceutical LLC filed Critical Reliable Biopharmaceutical LLC
Publication of AU2001259706A1 publication Critical patent/AU2001259706A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
AU2001259706A 2000-05-09 2001-05-09 Polymeric compounds useful as prodrugs Abandoned AU2001259706A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20279500P 2000-05-09 2000-05-09
US60202795 2000-05-09
PCT/US2001/015106 WO2001085751A1 (en) 2000-05-09 2001-05-09 Polymeric compounds useful as prodrugs

Publications (1)

Publication Number Publication Date
AU2001259706A1 true AU2001259706A1 (en) 2001-11-20

Family

ID=22751297

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259706A Abandoned AU2001259706A1 (en) 2000-05-09 2001-05-09 Polymeric compounds useful as prodrugs

Country Status (3)

Country Link
US (4) US20020013287A1 (en)
AU (1) AU2001259706A1 (en)
WO (1) WO2001085751A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1191097A1 (en) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
EA008741B1 (en) 2003-10-30 2007-08-31 Коли Фармасьютикал Гмбх C-class oligonucleotide analogs with enhanced immunostimulatory potency
US8188067B2 (en) 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
CN101065114A (en) * 2004-04-01 2007-10-31 特瓦制药工业有限公司 Imroved formulations of 6-mercaptopurine
CA2567789A1 (en) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
US20090312532A1 (en) * 2005-04-22 2009-12-17 Van Deutekom Judith Christina Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secodary rna structure
WO2007123391A1 (en) * 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
DK2049664T3 (en) * 2006-08-11 2012-01-02 Prosensa Technologies Bv Single-stranded oligonucleotides, complementary to repetitive elements, for the treatment of DNA repetitive instability-associated disorders
MX2009003398A (en) 2006-09-27 2009-08-12 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity.
CA2693742A1 (en) * 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
NZ582521A (en) * 2007-07-12 2011-09-30 Prosensa Technologies Bv A conjugate comprising the amino acid sequence LGAQSNF for targeting compounds to muscle tissue
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
PT2203173E (en) 2007-10-26 2016-03-15 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
CN101980726A (en) 2008-02-08 2011-02-23 普罗森那控股公司 Methods and means for treating DNA repeat instability associated genetic disorders
EP2110130A1 (en) * 2008-04-18 2009-10-21 Teva Pharmaceutical Industries Ltd. Pharmaceutical use of 6-mercaptopurine
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
JP5645840B2 (en) 2008-12-02 2014-12-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ Method for synthesizing phosphorous atom-modified nucleic acid
JP2013520395A (en) * 2009-02-22 2013-06-06 ケムジーンズ コーポレーション Synthesis of ara-2'-O-methyl-nucleosides, phosphoramidites and oligonucleotides incorporating novel modifications for biological applications such as therapeutics, diagnostics, G-tetradogenic oligonucleosides and aptamers
US20120046342A1 (en) 2009-04-24 2012-02-23 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
JP5707396B2 (en) 2009-06-17 2015-04-30 アイシス ファーマシューティカルズ， インコーポレーテッド Compositions and methods for modulation of SMN2 splicing in a subject
MX342945B (en) 2009-07-06 2016-10-18 Ontorii Inc * Novel nucleic acid prodrugs and methods use thereof.
EP2516647B1 (en) 2009-12-24 2016-12-14 BioMarin Technologies B.V. Molecule for treating an inflammatory disorder
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
JP5868324B2 (en) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ Asymmetric auxiliary group
RU2014105311A (en) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. METHODS FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
NZ627896A (en) 2012-01-27 2016-11-25 Biomarin Technologies B V Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
CN104684923B (en) 2012-07-13 2018-09-28 株式会社新日本科学 Chiral Nuclec acid adjuvants
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
US9926559B2 (en) 2013-01-09 2018-03-27 Biogen Ma Inc. Compositions and methods for modulation of SMN2 splicing in a subject
WO2015003747A1 (en) 2013-07-10 2015-01-15 Asteriapharma Gmbh Composition containing modified derivatives of a cytidine antimetabolite for the treatment of susceptible disease
JPWO2015108048A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antitumor agent having antitumor activity
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108046A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
SG11201605782UA (en) 2014-01-16 2016-08-30 Wave Life Sciences Ltd Chiral design
EP3797780B1 (en) * 2014-04-17 2022-09-14 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject
WO2015177062A1 (en) * 2014-05-21 2015-11-26 Rolic Ag Polymerizable dichroic dyes
WO2016040748A1 (en) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
WO2017066619A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
US11198867B2 (en) 2016-06-16 2021-12-14 Ionis Pharmaceuticals, Inc. Combinations for the modulation of SMN expression
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
BR112022016238A2 (en) 2020-02-28 2022-10-11 Ionis Pharmaceuticals Inc COMPOUNDS AND METHODS TO MODULATE SMN2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2088258C (en) * 1990-07-27 2004-09-14 Phillip Dan Cook Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
DK0677056T3 (en) * 1993-01-25 1996-08-05 Hybridon Inc Oligonucleotide alkyl phosphonates and alkyl phosphonothioates
US5457187A (en) * 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
JP3149319B2 (en) * 1994-07-22 2001-03-26 オリエンタル酵母工業株式会社 Method for producing recombinant GMT
ATE346918T1 (en) * 1998-06-19 2006-12-15 Univ Mcgill ANTISENSE OLIGONUCLEOTIDES BASED ON BETA-ARABINOSE AND ITS ANALOGUES

Also Published As

Publication number Publication date
US20070179112A1 (en) 2007-08-02
WO2001085751A1 (en) 2001-11-15
US20100081627A1 (en) 2010-04-01
US20020013287A1 (en) 2002-01-31
US20040132684A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AU2001259706A1 (en) Polymeric compounds useful as prodrugs
AU2002218266A1 (en) Novel indanylidene compounds
AU2001268475A1 (en) 7-phenyl-substituted tetracycline compounds
AU2002225730A1 (en) Compounds
AU2001241128A1 (en) Novel amide compounds
AU2001292030A1 (en) Antiparasitic compounds
AU2001292518A1 (en) Novel compounds
AU2001266345A1 (en) Five-membered-ring compound
AU2001239765A1 (en) Novel compounds
AUPQ661800A0 (en) Insulin-potentiating compounds
AU2001246998A1 (en) Novel compounds
AU2001266486A1 (en) New compounds useful as antibacterial agents
AU2001253362A1 (en) Novel compounds
AUPR059400A0 (en) Formaldehyde-releasing prodrugs
AU2002231077A1 (en) Novel compounds
AU2001256964A1 (en) Novel compounds
AU2000254942A1 (en) 7-phenyl-substituted tetracycline compounds
AU2002225724A1 (en) Motilide compounds
AU2002239405A1 (en) Tetrapartate prodrugs
AU5310500A (en) Pseudomycin prodrugs
AU2001250391A1 (en) Polymeric composition
AU2001230689A1 (en) Novel compounds
AU2002217285A1 (en) Compounds
EP1320553A4 (en) Novel polymer compounds
AU2002216060A1 (en) Novel compounds